<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02901366</url>
  </required_header>
  <id_info>
    <org_study_id>FYU-981-009</org_study_id>
    <nct_id>NCT02901366</nct_id>
  </id_info>
  <brief_title>Mass Balance Study of FYU-981</brief_title>
  <official_title>Plasma Concentration, Excretion and Mass Balance Orally Administered 14C-FYU-981 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fuji Yakuhin Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mochida Pharmaceutical Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fuji Yakuhin Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the plasma pharmacokinetics, the routes extent of elimination, and the metabolites
      of FYU-981 after a single 1 mg oral dose of 14C-FYU-981 in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (Cmax: Maximum plasma concentration)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC: Area under the plasma concentration-time curve)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Tmax: Time to reach the peak plasma concentration)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (T1/2: Elimination half-life of plasma concentration)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (kel: Elimination rate constant)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Vd/F: Distribution volume / Fraction of dose absorbed</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (CLtot/F: Total clearance / Fraction of dose absorbed)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (MRT: Mean residence time)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Ae(urine), Ae(feces) and Ae(air): Amount of radioactivity excreted in urine, feces, or air)</measure>
    <time_frame>168 hours or 72 hours (Ae(air))</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (fe(urine) , fe(feces) and fe(air): Fraction of radioactivity excreted in urine, feces, or air)</measure>
    <time_frame>168 hours or 72 hours (Ae(air))</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Ae(total): Total amount of radioactivity excreted)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (fe(total): Total fraction of radioactivity excreted)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Ae(urine + air): Amount of radioactivity excreted in urine and air)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (fe(urine + air): Fraction of radioactivity excreted in urine and air)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Ratios of FYU-981 and its metabolites in plasma, urine and feces)</measure>
    <time_frame>168 hours</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy Male Subjects</condition>
  <arm_group>
    <arm_group_label>14C-FYU-981</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14C-FYU-981, (Oral single dosing)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-FYU-981</intervention_name>
    <description>14C-FYU-981, (Oral single dosing)</description>
    <arm_group_label>14C-FYU-981</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese healthy adult subjects

          -  Body mass index: &gt;=18.5 and &lt;25.0

        Exclusion Criteria:

          -  Subjects with any disease or any history of diseases that might be unsuitable for
             participation in the clinical study

          -  Have participated in a [14C]-study within the last 12 months prior to dosing of the
             investigational drug

          -  Exposure to radiation for therapeutic or diagnostic reasons (except dental X-rays and
             plain X-rays of thorax and bony skeleton) within the last 12 months prior to dosing of
             the investigational drug

          -  Occupationally exposed worker
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2016</study_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mass balance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

